Skip to content

Tumour Sites
- Breast
- Colorectal
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Career Hub
- View Openings
- Post A Job
About Us
My Account
Search

Menu

Tumour Sites
- Breast
- Colorectal
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Career Hub
- View Openings
- Post A Job
About Us
My Account
Search

Login
Register
My Account
- Edit Profile
search

Login
Register
My Account
- Edit Profile
search

Search for:

EHA Highlights 2024 Roundtable Discussions

EHA Highlights 2024 Roundtable Discussions

EHA Highlights 2024

Videos

Leukemia

Dr. Jorge Cortes

Dr. Julie Bergeron

Dr.-Julie-Bergeron-e1719328942827.jpg

Dr. Aniket Bankar

Dr.-Aniket-Bankar.jpg

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: A COMPARISON OF THE CONSECUTIVE HOVON-100 AND H-146 STUDIES

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: PHALLCON TRIAL

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: REVUMENIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD+ AML WHO RECEIVED CONTINUATION THERAPY

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: GENETIC INSIGHTS INTO ACQUIRED RESISTANCE AND CLONAL EVOLUTION IN VEN-BASED THERAPY FOR AML

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: SECONDARY-TYPE MUTATIONS IN ELN 2022 FAVORABLE RISK AML & RESULTS FROM THE HARMONY PLATFORM

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: ASC4FIRST STUDY

Lymphoma

Dr. Robert Kridel

Dr. Robert Kridel

Dr. Kerry Savage

Dr. Kerry Savage

Dr. Diego Villa

Dr. Diego Villa

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: RANDOMIZED STUDY GHSG HD21

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: STARGLO

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: ECHO TRIAL

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: BGB-16673-101 STUDY

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: EPCORE CLL-1 TRIAL

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: AN UPDATED ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

Multiple Myeloma

Dr. Donna Reece

Dr. Darrell White

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Dr. Maria Victoria Mateos Manteca

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: GMMG-HD7 TRIAL

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: ISA PLUS LEN/DEX/BORTEZOMIB VS ISARD IN PATIENTS NDMM TI

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: >6-YEAR UPDATE OF CASSIOPEIA

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: CARTITUDE-2 COHORT D

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: PHASE 2 STUDY OF FULLY HUMAN BCMA-TARGETING CAR-T CELLS

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: CAMMA 2 STUDY

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: RP2D OF ABBV-383, A BCMA BISPECIFIC ANTIBODY, IN PATIENTS WITH RRMM

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: RESULTS FROM DREAMM-7

Podcasts

Leukemia

Dr. Jorge Cortes

Dr. Julie Bergeron

Dr.-Brezden-Masley-Photo-scaled-e1701794414740.jpg

Dr. Aniket Bankar

Dr.-Aniket-Bankar.jpg

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: A COMPARISON OF THE CONSECUTIVE HOVON-100 AND H-146 STUDIES

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: PHALLCON TRIAL

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: REVUMENIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD+ AML WHO RECEIVED CONTINUATION THERAPY

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: GENETIC INSIGHTS INTO ACQUIRED RESISTANCE AND CLONAL EVOLUTION IN VEN-BASED THERAPY FOR AML

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: SECONDARY-TYPE MUTATIONS IN ELN 2022 FAVORABLE RISK AML & RESULTS FROM THE HARMONY PLATFORM

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: ASC4FIRST STUDY

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: APOLLO TRIAL

2024

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: RESULTS FROM THE HARMONY PLATFORM

Lymphoma

Dr. Robert Kridel

Dr. Robert Kridel

Dr. Kerry Savage

Dr. Kerry Savage

Dr. Diego Villa

Dr. Diego Villa

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: RANDOMIZED STUDY GHSG HD21

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: STARGLO

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: ECHO TRIAL

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: BGB-16673-101 STUDY

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: EPCORE CLL-1 TRIAL

2024

EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: AN UPDATED ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

Multiple Myeloma

Dr. Donna Reece

Dr. Darrell White

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Dr. Maria Victoria Mateos Manteca

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: GMMG-HD7 TRIAL

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: ISA PLUS LEN/DEX/BORTEZOMIB VS ISARD IN PATIENTS NDMM TI

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: >6-YEAR UPDATE OF CASSIOPEIA

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: CARTITUDE-2 COHORT D

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: PHASE 2 STUDY OF FULLY HUMAN BCMA-TARGETING CAR-T CELLS

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: CAMMA 2 STUDY

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: RP2D OF ABBV-383, A BCMA BISPECIFIC ANTIBODY, IN PATIENTS WITH RRMM

2024

EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: RESULTS FROM DREAMM-7

To Top

Tagged page-parent-for-videos-or-podcasts

© All rights reserved

Made with ❤ by Elementor

Oncology Career Hub
Post A Job
Scientific Steering Committee
Events

About Us
Contact Us
Disclaimer
MDBriefcase

199 Bay Street #4000
Toronto, ON M5L 1A9

©2024 Oncology Education a Think Research company. All rights reserved. Privacy Policy. Accessibility Statement.

Twitter Instagram Facebook-f Linkedin-in

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Tumour Sites
- Breast
- Colorectal
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Oncology Career Hub
- View Openings
- Post A Job
About Us

Login
Register

Search for:

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. See our privacy policy and cookie policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!